Figure 2

![Figure 2: Blood biomarker results from the randomized clinical trial of EGb 761 (Ginkgo biloba extract) in mild cognitive impairment. The study measured inflammatory and oxidative stress markers, investigating their relationship to beta-amyloid and phosphorylated tau pathology.]()

> Source: Xavier Morató et al. "A randomized, open-label clinical trial in mild cognitive impairment with EGb 76." *Scientific reports*, 2023. PMID: [37012306](https://pubmed.ncbi.nlm.nih.gov/37012306/)

<figure>
  <img src="" alt="Blood biomarker results from the randomized clinical trial of EGb 761 (Ginkgo biloba extract) in mild cognitive impairment. The study measured inflammatory and oxidative stress markers, investigating their relationship to beta-amyloid and phosphorylated tau pathology." />
  <figcaption>Figure 2. Blood biomarker results from the randomized clinical trial of EGb 761 (Ginkgo biloba extract) in mild cognitive impairment. The study measured inflammatory and oxidative stress markers, investigating their relationship to beta-amyloid and phosphorylated tau pathology.<br>  Source: Xavier Morató et al. "A randomized, open-label clinical trial in mild cognitive impairment with EGb 76." <em>Scientific reports</em>, 2023. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37012306/">37012306</a></figcaption>
</figure>